Sotorasib: First Approval-Reference-Cited by-同舟云学术

Sotorasib: First Approval

Published:2021-08-06 Issue:13 Volume:81 Page:1573-1579
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Blair Hannah A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-021-01574-2.pdf

Reference26 articles.

1. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–23.

2. Kim D, Xue JY, Lito P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell. 2020;183(4):850–9.

3. Singh RR, O’Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs. 2020;80(7):647–69.

4. Amgen. Amgen announces first clinical data evaluating novel investigational KRASG12C inhibitor AMG 510 at ASCO 2019 [media release]. 3 Jun 2019. https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019.

5. Amgen. Amgen's sotorasib granted breakthrough therapy designation for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation [media release]. 8 Dec 2020. https://www.amgen.com/newsroom/press-releases/2020/12/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-nonsmall-cell-lung-cancer-patients-with-kras-g12c-mutation.

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience;Biomedicines;2024-01-31

2. Dissecting the pleiotropic roles of reactive oxygen species (ROS) in lung cancer: From carcinogenesis toward therapy;Medicinal Research Reviews;2024-01-29

3. Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit;Journal of Medicinal Chemistry;2024-01-23

4. Therapeutic targeting of KRAS mutation-driven tumorigenesis by extracellular vesicles loaded with small interfering RNA;2024-01-20

5. Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients;2024-01-19